erythromycin ethyl succinate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, produced by Streptomyces strains	1051	1264-62-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: erythromycin ethylsuccinate erythromycin ethyl succinate anamycin arpimycin eritrocina erythrocin ethyl succinate	A macrolide antibiotic, produced by Streptomyces erythreus. This compound is an ester of erythromycin base and succinic acid. It acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Molecular weight: 862.06 Formula: C43H75NO16 CLOGP: 3.25 LIPINSKI: 2 HAC: 17 HDO: 4 TPSA: 226.28 ALOGS: -3.76 ROTB: 14 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

erythromycin ethylsuccinate
erythromycin ethyl succinate
anamycin
arpimycin
eritrocina
erythrocin ethyl succinate

A macrolide antibiotic, produced by Streptomyces erythreus. This compound is an ester of erythromycin base and succinic acid. It acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.

Molecular weight: 862.06
Formula: C43H75NO16
CLOGP: 3.25
LIPINSKI: 2
HAC: 17
HDO: 4
TPSA: 226.28
ALOGS: -3.76
ROTB: 14

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
April 2, 1965	FDA	ARBOR PHARMS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	4580.36	12.44	2249	22029	308438	63156306
International normalised ratio fluctuation	227.91	12.44	69	24209	2409	63462335
Bloody discharge	176.81	12.44	51	24227	1500	63463244
Lyme disease	133.13	12.44	50	24228	3399	63461345
Abortion spontaneous	112.52	12.44	113	24165	47082	63417662
Seronegative arthritis	109.19	12.44	45	24233	3914	63460830
Exposure during pregnancy	68.26	12.44	170	24108	155377	63309367
Dislocation of vertebra	58.16	12.44	38	24240	8597	63456147
Anaphylactic reaction	57.49	12.44	96	24182	66004	63398740
Maternal exposure during pregnancy	53.28	12.44	195	24083	219867	63244877
Vomiting	52.77	12.44	380	23898	559237	62905507
Faecal volume decreased	50.20	12.44	12	24266	165	63464579
Drug interaction	47.26	12.44	193	24085	228938	63235806
Amniotic cavity infection	44.03	12.44	17	24261	1246	63463498
Wheezing	42.44	12.44	105	24173	95490	63369254
Spondylitis	41.71	12.44	24	24254	4330	63460414
Pneumococcal infection	38.98	12.44	12	24266	443	63464301
Completed suicide	38.71	12.44	5	24273	145668	63319076
Death	37.67	12.44	53	24225	374328	63090416
Mass excision	37.45	12.44	11	24267	345	63464399
Umbilical erythema	36.56	12.44	8	24270	72	63464672
Rash	35.28	12.44	348	23930	560523	62904221
Drug intolerance	33.99	12.44	218	24060	308443	63156301
Spinal fusion surgery	33.65	12.44	23	24255	5605	63459139
Vertigo positional	33.58	12.44	18	24260	2831	63461913
Wound infection	33.26	12.44	41	24237	21369	63443375
Purpura senile	32.49	12.44	11	24267	552	63464192
Pain	31.59	12.44	161	24117	740467	62724277
Necrosis ischaemic	31.50	12.44	12	24266	848	63463896
Adjustment disorder with depressed mood	31.09	12.44	28	24250	10176	63454568
Caesarean section	30.38	12.44	35	24243	16997	63447747
Premature baby	29.50	12.44	38	24240	20697	63444047
Infection	29.10	12.44	168	24110	229005	63235739
Tarsal tunnel syndrome	28.41	12.44	10	24268	564	63464180
Urticaria	27.56	12.44	131	24147	165671	63299073
Ototoxicity	26.17	12.44	12	24266	1350	63463394
Serum sickness-like reaction	25.68	12.44	9	24269	501	63464243
Bronchial obstruction	25.01	12.44	12	24266	1495	63463249
Drug tolerance decreased	24.82	12.44	32	24246	17441	63447303
Benign laryngeal neoplasm	24.63	12.44	5	24273	30	63464714
Beta haemolytic streptococcal infection	24.45	12.44	13	24265	2012	63462732
Ulcerative keratitis	23.49	12.44	14	24264	2696	63462048
Breast cancer stage III	23.15	12.44	24	24254	10362	63454382
Therapeutic product effect incomplete	23.15	12.44	102	24176	124954	63339790
Pneumonia streptococcal	22.92	12.44	12	24266	1799	63462945
Premature delivery	22.44	12.44	41	24237	30240	63434504
Stevens-Johnson syndrome	21.36	12.44	36	24242	24914	63439830
Monocytosis	21.15	12.44	8	24270	554	63464190
Resorption bone increased	20.71	12.44	10	24268	1264	63463480
Neutropenia	20.49	12.44	22	24256	174983	63289761
Lip swelling	20.46	12.44	40	24238	31023	63433721
Grip strength decreased	20.21	12.44	33	24245	22254	63442490
Death neonatal	20.03	12.44	9	24269	966	63463778
Premature rupture of membranes	19.93	12.44	16	24262	4977	63459767
Vestibular disorder	19.60	12.44	10	24268	1421	63463323
Abdominal pain upper	19.23	12.44	140	24138	206304	63258440
Walking aid user	19.08	12.44	22	24256	10695	63454049
Corneal neovascularisation	18.63	12.44	5	24273	112	63464632
Iron deficiency	18.49	12.44	18	24260	7212	63457532
Oligohydramnios	18.48	12.44	17	24261	6349	63458395
Mucous stools	17.78	12.44	14	24264	4234	63460510
Corneal perforation	17.77	12.44	7	24271	541	63464203
Pharyngeal oedema	17.74	12.44	24	24254	13697	63451047
Fall	17.40	12.44	84	24194	392250	63072494
Morbid thoughts	16.90	12.44	7	24271	616	63464128
Hypotension	16.84	12.44	51	24227	272553	63192191
Alopecia	16.31	12.44	70	24208	337466	63127278
Anaemia	15.99	12.44	58	24220	293372	63171372
Live birth	15.68	12.44	32	24246	25598	63439146
Prescribed overdose	15.66	12.44	38	24240	34115	63430629
Infantile haemangioma	15.52	12.44	4	24274	76	63464668
Starvation ketoacidosis	15.24	12.44	4	24274	82	63464662
Nodule	14.99	12.44	28	24250	20998	63443746
Type 2 diabetes mellitus	14.91	12.44	56	24222	63812	63400932
Pharyngeal swelling	14.64	12.44	15	24263	6389	63458355
Ergot poisoning	14.60	12.44	4	24274	97	63464647
Cardiac arrest neonatal	14.45	12.44	4	24274	101	63464643
Anal candidiasis	14.38	12.44	3	24275	21	63464723
Drug abuse	14.18	12.44	5	24273	72513	63392231
Toxicity to various agents	14.05	12.44	48	24230	247202	63217542
Dysphoria	13.91	12.44	13	24265	4953	63459791
Stenotrophomonas infection	13.84	12.44	9	24269	2018	63462726
Drug ineffective	13.49	12.44	301	23977	1044464	62420280
Delirium	13.23	12.44	46	24232	50495	63414249
Epidermolysis	13.10	12.44	6	24272	673	63464071
Jarisch-Herxheimer reaction	12.88	12.44	5	24273	372	63464372
Disease progression	12.69	12.44	17	24261	122741	63342003
Febrile neutropenia	12.66	12.44	16	24262	118433	63346311
Disability	12.54	12.44	24	24254	18323	63446421
Exposure to SARS-CoV-2	12.52	12.44	8	24270	1743	63463001
Product packaging issue	12.50	12.44	7	24271	1199	63463545

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	475.82	15.35	278	8461	80251	34867941
Hyphaema	78.47	15.35	20	8719	567	34947625
Toxic epidermal necrolysis	75.77	15.35	54	8685	21592	34926600
Drug interaction	63.70	15.35	160	8579	225786	34722406
Product packaging issue	62.13	15.35	17	8722	637	34947555
Premature baby	51.01	15.35	41	8698	19592	34928600
Dystonia	44.87	15.35	30	8709	10815	34937377
Low birth weight baby	43.01	15.35	26	8713	7879	34940313
Rhabdomyolysis	41.91	15.35	67	8672	68096	34880096
Stupor	40.61	15.35	18	8721	2873	34945319
Acute generalised exanthematous pustulosis	38.71	15.35	23	8716	6753	34941439
Coagulation time prolonged	35.27	15.35	13	8726	1289	34946903
Eye pain	34.72	15.35	28	8711	13434	34934758
Obstruction gastric	34.56	15.35	12	8727	1001	34947191
Intraocular pressure increased	32.67	15.35	19	8720	5364	34942828
Pyloric stenosis	32.33	15.35	11	8728	863	34947329
Brain oedema	32.00	15.35	27	8712	13794	34934398
Foetal death	31.37	15.35	8	8731	227	34947965
Product dispensing error	29.98	15.35	19	8720	6255	34941937
Deafness bilateral	29.72	15.35	11	8728	1103	34947089
Clonal haematopoiesis	27.95	15.35	6	8733	78	34948114
Ototoxicity	27.13	15.35	12	8727	1905	34946287
Learning disorder	26.30	15.35	10	8729	1081	34947111
Cellulitis enterococcal	26.18	15.35	6	8733	107	34948085
Foetal arrhythmia	26.13	15.35	6	8733	108	34948084
Oligohydramnios	23.42	15.35	7	8732	361	34947831
Onychophagia	23.37	15.35	5	8734	64	34948128
Torsade de pointes	22.97	15.35	17	8722	7192	34941000
Caesarean section	22.68	15.35	11	8728	2153	34946039
Oculogyric crisis	22.68	15.35	10	8729	1576	34946616
Mixed liver injury	22.52	15.35	12	8727	2861	34945331
Potentiating drug interaction	21.14	15.35	14	8725	4963	34943229
Respiratory acidosis	20.96	15.35	14	8725	5036	34943156
Pathogen resistance	20.88	15.35	18	8721	9464	34938728
Sepsis neonatal	20.86	15.35	6	8733	270	34947922
Vasculitic rash	20.30	15.35	8	8731	951	34947241
Myasthenia gravis crisis	19.75	15.35	7	8732	620	34947572
Hepatic necrosis	19.41	15.35	12	8727	3782	34944410
Mycoplasma infection	18.51	15.35	6	8733	405	34947787
Megacolon	18.37	15.35	9	8730	1801	34946391
Ischaemic hepatitis	18.28	15.35	9	8730	1819	34946373
Myoglobinuria	18.19	15.35	7	8732	781	34947411
Accidental exposure to product	18.06	15.35	19	8720	12783	34935409
Neonatal disorder	17.84	15.35	7	8732	823	34947369
Cardio-respiratory arrest neonatal	17.73	15.35	3	8736	9	34948183
Tricuspid valve disease	17.67	15.35	5	8734	212	34947980
Foetal exposure during pregnancy	17.56	15.35	33	8706	38068	34910124
Measles	17.41	15.35	5	8734	224	34947968
Stevens-Johnson syndrome	16.82	15.35	22	8717	18617	34929575
Akinesia	16.77	15.35	9	8730	2175	34946017
Brain herniation	16.36	15.35	11	8728	3997	34944195
Visual acuity reduced	16.06	15.35	20	8719	16129	34932063
Hepatic failure	16.03	15.35	30	8709	34501	34913691
Swelling face	15.98	15.35	24	8715	23081	34925111
Proteus infection	15.90	15.35	7	8732	1099	34947093
Exposure during pregnancy	15.81	15.35	15	8724	8919	34939273
Pneumonia mycoplasmal	15.73	15.35	6	8733	654	34947538
Pupillary disorder	15.68	15.35	5	8734	320	34947872

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	3172.79	12.04	1678	25483	297238	79419989
International normalised ratio fluctuation	217.28	12.04	70	27091	3384	79713843
Bloody discharge	175.38	12.04	52	27109	1901	79715326
Lyme disease	140.19	12.04	50	27111	3300	79713927
Maternal exposure during pregnancy	111.81	12.04	181	26980	136357	79580870
Drug interaction	97.78	12.04	337	26824	414846	79302381
Seronegative arthritis	96.92	12.04	42	27119	4650	79712577
Abortion spontaneous	96.10	12.04	80	27081	29427	79687800
Product packaging issue	73.53	12.04	24	27137	1209	79716018
Dislocation of vertebra	65.42	12.04	38	27123	7842	79709385
Hyphaema	63.79	12.04	20	27141	884	79716343
Toxic epidermal necrolysis	58.45	12.04	74	27087	44507	79672720
Exposure during pregnancy	51.11	12.04	109	27052	101023	79616204
Ototoxicity	44.73	12.04	22	27139	3252	79713975
Wheezing	43.89	12.04	112	27049	116552	79600675
Drug abuse	43.72	12.04	3	27158	162688	79554539
Anaphylactic reaction	43.17	12.04	91	27070	83652	79633575
Drug intolerance	42.96	12.04	191	26970	263928	79453299
Stevens-Johnson syndrome	39.16	12.04	57	27104	39109	79678118
Spinal fusion surgery	37.59	12.04	23	27138	5215	79712012
Adjustment disorder with depressed mood	36.78	12.04	28	27133	9058	79708169
Infection	36.47	12.04	171	26990	241541	79475686
Death	36.07	12.04	88	27073	566426	79150801
Pneumococcal infection	35.23	12.04	13	27148	945	79716282
Completed suicide	35.15	12.04	20	27141	245747	79471480
Wound infection	34.95	12.04	42	27119	23949	79693278
Spondylitis	34.53	12.04	21	27140	4710	79712517
Febrile neutropenia	34.20	12.04	18	27143	230981	79486246
Mass excision	34.00	12.04	10	27151	355	79716872
Drug tolerance decreased	33.81	12.04	31	27130	12947	79704280
Rash	33.51	12.04	322	26839	578036	79139191
Vomiting	32.09	12.04	357	26804	665471	79051756
Stupor	31.91	12.04	23	27138	6849	79710378
Anaemia	31.68	12.04	65	27096	444950	79272277
Ulcerative keratitis	31.18	12.04	18	27143	3671	79713556
Caesarean section	30.84	12.04	29	27132	12506	79704721
Purpura senile	30.33	12.04	10	27151	520	79716707
Tarsal tunnel syndrome	30.22	12.04	10	27151	526	79716701
Vertigo positional	30.16	12.04	17	27144	3313	79713914
Necrosis ischaemic	30.08	12.04	12	27149	1078	79716149
Learning disorder	29.46	12.04	10	27151	569	79716658
Neutropenia	27.03	12.04	35	27126	287675	79429552
Breast cancer stage III	26.64	12.04	24	27137	9802	79707425
Coagulation time prolonged	26.08	12.04	14	27147	2481	79714746
Intraocular pressure increased	25.98	12.04	23	27138	9182	79708045
Beta haemolytic streptococcal infection	25.44	12.04	13	27148	2084	79715143
Hypotension	25.25	12.04	72	27089	440245	79276982
Torsade de pointes	25.22	12.04	32	27129	19280	79697947
Benign laryngeal neoplasm	25.21	12.04	5	27156	30	79717197
Deafness bilateral	24.93	12.04	13	27148	2172	79715055
Pneumonia streptococcal	24.83	12.04	14	27147	2731	79714496
Serum sickness-like reaction	24.77	12.04	9	27152	626	79716601
Premature delivery	24.69	12.04	35	27126	23432	79693795
Live birth	24.38	12.04	31	27130	18713	79698514
Product dispensing error	24.03	12.04	26	27135	13237	79703990
Respiratory acidosis	23.96	12.04	24	27137	11176	79706051
Urticaria	23.64	12.04	125	27036	185076	79532151
Grip strength decreased	23.58	12.04	33	27128	21836	79695391
Type 2 diabetes mellitus	22.68	12.04	56	27105	57066	79660161
Therapeutic product effect incomplete	22.66	12.04	102	27059	141543	79575684
Malignant neoplasm progression	22.60	12.04	9	27152	135981	79581246
Walking aid user	22.18	12.04	22	27139	10126	79707101
Corneal neovascularisation	22.12	12.04	6	27155	158	79717069
Acute generalised exanthematous pustulosis	21.60	12.04	28	27133	17226	79700001
Pharyngeal oedema	21.30	12.04	27	27134	16245	79700982
Oculogyric crisis	21.28	12.04	13	27148	2939	79714288
Resorption bone increased	20.41	12.04	10	27151	1465	79715762
Premature rupture of membranes	19.77	12.04	14	27147	4055	79713172
Rheumatic fever	19.58	12.04	35	27126	28490	79688737
Hyponatraemia	19.58	12.04	19	27142	177829	79539398
Oligohydramnios	19.56	12.04	13	27148	3399	79713828
Eye pain	19.55	12.04	41	27120	37537	79679690
Bronchial obstruction	19.47	12.04	12	27149	2756	79714471
Lip swelling	19.40	12.04	43	27118	40868	79676359
Pathogen resistance	19.10	12.04	24	27137	14318	79702909
Swelling face	18.62	12.04	60	27101	71152	79646075
Rhabdomyolysis	18.59	12.04	77	27084	103054	79614173
Abdominal rigidity	18.27	12.04	12	27149	3076	79714151
Ergot poisoning	18.21	12.04	5	27156	138	79717089
Haemoglobin decreased	17.94	12.04	30	27131	222089	79495138
Dermatitis allergic	17.56	12.04	26	27135	18104	79699123
Monocytosis	17.41	12.04	8	27153	1016	79716211
Dystonia	16.98	12.04	28	27133	21371	79695856
Morbid thoughts	15.98	12.04	7	27154	795	79716432
Prescribed overdose	15.96	12.04	38	27123	37845	79679382
Abdominal pain upper	15.67	12.04	130	27031	223689	79493538
Vestibular disorder	15.65	12.04	10	27151	2445	79714782
Fall	15.43	12.04	100	27061	487529	79229698
Cardio-respiratory arrest	15.26	12.04	9	27152	108501	79608726
Hip arthroplasty	15.21	12.04	36	27125	35720	79681507
Disease progression	14.80	12.04	25	27136	184337	79532890
Confusional state	14.77	12.04	57	27104	317940	79399287
Asthenia	14.68	12.04	108	27053	511581	79205646
Amnesia	14.60	12.04	51	27110	63006	79654221
Swollen joint count increased	14.31	12.04	27	27134	22900	79694327
Anal candidiasis	14.26	12.04	3	27158	25	79717202
Blood glucose increased	14.21	12.04	11	27150	114964	79602263
Platelet count decreased	14.19	12.04	28	27133	194636	79522591
Toxicity to various agents	14.08	12.04	85	27076	421455	79295772
Myoglobinuria	13.87	12.04	7	27154	1093	79716134
Myasthenia gravis crisis	13.80	12.04	7	27154	1104	79716123
Cardiac arrest neonatal	13.77	12.04	3	27158	30	79717197
Potentiating drug interaction	13.77	12.04	16	27145	8803	79708424
Brain oedema	13.65	12.04	28	27133	25235	79691992
Starvation ketoacidosis	13.55	12.04	4	27157	144	79717083
Measles	13.14	12.04	5	27156	396	79716831
Corneal perforation	13.10	12.04	6	27155	757	79716470
Disability	13.05	12.04	22	27139	17098	79700129
Iron deficiency	12.89	12.04	17	27144	10637	79706590
Tricuspid valve disease	12.78	12.04	5	27156	427	79716800
Liver function test increased	12.74	12.04	36	27125	39737	79677490
Amniotic cavity infection	12.64	12.04	6	27155	821	79716406
Platelet count increased	12.30	12.04	25	27136	22381	79694846
Exposure to SARS-CoV-2	12.23	12.04	8	27153	2036	79715191
Sensation of foreign body	12.12	12.04	12	27149	5510	79711717
Delirium	12.10	12.04	59	27102	84568	79632659
Corneal deposits	12.09	12.04	5	27156	493	79716734
Ischaemic hepatitis	12.06	12.04	10	27151	3654	79713573

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA CS	M0028311	Macrolides
FDA PE	N0000009982	Decreased Sebaceous Gland Activity
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D011500	Protein Synthesis Inhibitors
FDA EPC	N0000175877	Macrolide
FDA EPC	N0000175935	Macrolide Antimicrobial

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Meningitis	indication	7180009	DOID:9471
Bacterial septicemia	indication	10001005	DOID:0040085
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Bacterial pneumonia	indication	53084003	DOID:874
Urinary tract infectious disease	indication	68566005
Hepatic coma	indication	72836002	DOID:12550
Cholangitis	indication	82403002	DOID:9446
Infection of bone	indication	111253001
Infectious disease of abdomen	indication	128070006
Infectious disorder of joint	indication	363162000
Preoperative Bowel Preparation	indication
Burn Wound Infections	indication
Acute tuberculosis	off-label use	25629007
Pulmonary tuberculosis	off-label use	154283005	DOID:2957
Hypocalcemia	contraindication	5291005
Parkinsonism	contraindication	32798002
Dehydration	contraindication	34095006
Tinnitus	contraindication	60862001
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Pregnancy, function	contraindication	289908002
Vertigo	contraindication	399153001
Infant Botulism	contraindication
Disorder of the 8th Cranial Nerve	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.61	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4017592	VUID
N0000145973	NUI
4017592	VANDF
4017594	VANDF
C0014810	UMLSCUI
CHEBI:31555	CHEBI
CHEBI:42355	CHEBI
CHEMBL1200688	ChEMBL_ID
D015643	MESH_DESCRIPTOR_UI
1014KSJ86F	UNII
443953	PUBCHEM_CID
DB00199	DRUGBANK_ID
151373	RXNORM
33314	MMSL
42396	MMSL
4543	MMSL
4675	MMSL
4677	MMSL
4799	MMSL
72164	MMSL
d00046	MMSL
002755	NDDF
002757	NDDF
12578001	SNOMEDCT_US
30427009	SNOMEDCT_US
372694001	SNOMEDCT_US
C0014806	UMLSCUI
39	INN_ID
12560	PUBCHEM_CID
D004917	MESH_DESCRIPTOR_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL	HUMAN PRESCRIPTION DRUG LABEL	2	21695-690	GRANULE, FOR SUSPENSION	200 mg	ORAL	ANDA	26 sections
E.E.S 400	HUMAN PRESCRIPTION DRUG LABEL	1	24338-100	TABLET	400 mg	ORAL	ANDA	27 sections
E.E.S 400	HUMAN PRESCRIPTION DRUG LABEL	1	24338-100	TABLET	400 mg	ORAL	ANDA	27 sections
ERYTHROMYCIN ETHYLSUCCINATE	HUMAN PRESCRIPTION DRUG LABEL	1	24338-110	TABLET	400 mg	ORAL	ANDA	26 sections
ERYTHROMYCIN ETHYLSUCCINATE	HUMAN PRESCRIPTION DRUG LABEL	1	24338-110	TABLET	400 mg	ORAL	ANDA	26 sections
Ery-Ped	HUMAN PRESCRIPTION DRUG LABEL	1	24338-130	SUSPENSION	400 mg	ORAL	NDA	27 sections
Ery-Ped	HUMAN PRESCRIPTION DRUG LABEL	1	24338-130	SUSPENSION	400 mg	ORAL	NDA	27 sections
Ery-Ped	HUMAN PRESCRIPTION DRUG LABEL	1	24338-132	SUSPENSION	200 mg	ORAL	NDA	27 sections
Ery-Ped	HUMAN PRESCRIPTION DRUG LABEL	1	24338-132	SUSPENSION	200 mg	ORAL	NDA	27 sections
E.E.S	HUMAN PRESCRIPTION DRUG LABEL	1	24338-134	GRANULE, FOR SUSPENSION	200 mg	ORAL	NDA	27 sections
E.E.S	HUMAN PRESCRIPTION DRUG LABEL	1	24338-134	GRANULE, FOR SUSPENSION	200 mg	ORAL	NDA	27 sections
E.E.S	HUMAN PRESCRIPTION DRUG LABEL	1	24338-136	GRANULE, FOR SUSPENSION	200 mg	ORAL	NDA	27 sections
E.E.S	HUMAN PRESCRIPTION DRUG LABEL	1	24338-136	GRANULE, FOR SUSPENSION	200 mg	ORAL	NDA	27 sections
ERYTHROMYCIN ETHYLSUCCINATE	HUMAN PRESCRIPTION DRUG LABEL	1	52536-130	SUSPENSION	400 mg	ORAL	NDA	27 sections
ERYTHROMYCIN ETHYLSUCCINATE	HUMAN PRESCRIPTION DRUG LABEL	1	52536-132	SUSPENSION	200 mg	ORAL	NDA	27 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	52536-134	GRANULE, FOR SUSPENSION	200 mg	ORAL	NDA	28 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	52536-136	GRANULE, FOR SUSPENSION	200 mg	ORAL	NDA	28 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	54868-0018	TABLET	400 mg	ORAL	ANDA	13 sections
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL	HUMAN PRESCRIPTION DRUG LABEL	2	54868-0971	GRANULE, FOR SUSPENSION	200 mg	ORAL	ANDA	26 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-440	GRANULE, FOR SUSPENSION	200 mg	ORAL	ANDA	23 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-440	GRANULE, FOR SUSPENSION	200 mg	ORAL	ANDA	23 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-630	GRANULE, FOR SUSPENSION	200 mg	ORAL	ANDA	22 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-631	GRANULE, FOR SUSPENSION	400 mg	ORAL	ANDA	22 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2500	GRANULE, FOR SUSPENSION	200 mg	ORAL	NDA	27 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2500	GRANULE, FOR SUSPENSION	200 mg	ORAL	NDA	27 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	69238-1503	SUSPENSION	200 mg	ORAL	ANDA	19 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	69238-1503	SUSPENSION	200 mg	ORAL	ANDA	19 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	69238-1504	SUSPENSION	400 mg	ORAL	ANDA	19 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	69238-1504	SUSPENSION	400 mg	ORAL	ANDA	19 sections
Erythromycin ethylsuccinate	Human Prescription Drug Label	1	71209-102	FOR SUSPENSION	200 mg	ORAL	ANDA	22 sections